Back to today’s briefing

Story perspectives

Trodelvy and Keytruda Cut Tumor Progression by 35%

6/1/2025

28 2

Summary

Story summary

In a groundbreaking development, Gilead Sciences’ Trodelvy, when paired with Merck’s Keytruda, has shown a remarkable 35% reduction in tumor progression risk for metastatic triple-negative breast cancer in the ASCENT-04 trial. This promising combination could redefine treatment standards, but emerging competitors like sacituzumab tiragol can threaten Trodelvy's foothold in the market.

1 of 1

Story summary

In a groundbreaking development, Gilead Sciences’ Trodelvy, when paired with Merck’s Keytruda, has shown a remarkable 35% reduction in tumor progression risk for metastatic triple-negative breast cancer in the ASCENT-04 trial. This promising combination could redefine treatment standards, but emerging competitors like sacituzumab tiragol can threaten Trodelvy's foothold in the market.